Ruxolitinib—a potent JAK1/JAK2 inhibitor—is approved to treat hydroxyurea intolerant/refractory PV, high-risk myelofibrosis (MF) which includes: primary MF, post–polycythemia vera MF and post-essential thrombocythemia MF. The gene discussed is JAK2; the disease is acquired polycythemia vera.